Drug news
Stiefel takes world rights to Toctino from Basilea for Chronic Hand Eczema
Stiefel,a unit of GSK, is gaining exclusive worldwide rights to Toctino (alitretinoin.) from Basilea Pharma. Toctino is commercially available in 14 countries (and approved in an additional 15) for severe Chronic Hand Eczema that is refractory to treatment with potent topical corticosteroids. In the USA, oral alitretinoin is in a Phase III trial.
Stiefel will assume responsibility for the development of the product in the USA and take on existing Toctino distribution agreements in Europe, Canada, Mexico, Israel and South Korea.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
6 mins